Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
This article was originally published in PharmAsia News
Executive Summary
Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies